Trials / Terminated
TerminatedNCT03357133
Tirofiban for Patients Treated With Alteplase
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Early Administration of Tirofiban in Acute Ischemic Stroke Patients Treated With Intravenous Alteplase Thrombolysis
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirofiban | Tirofiban Injection after the alteplase intravenous thrombolysis |
| DRUG | Alteplase | Only alteplase intravenous thrombolysis |
Timeline
- Start date
- 2017-12-16
- Primary completion
- 2020-06-01
- Completion
- 2020-08-31
- First posted
- 2017-11-29
- Last updated
- 2020-09-09
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03357133. Inclusion in this directory is not an endorsement.